Invivyd, Inc. (NASDAQ:IVVD) Stock Now Rated "Hold" by Wall Street Analysts

Key Points

• Analyst sentiment is mixed: Six brokerages give Invivyd an average “Hold” rating—three Buys, two Holds, and one Sell—with an average 12-month price target of $10.
• Invivyd shares opened at $0.57, down 3.7%, near their 52-week low of $0.53.
• The company reported a quarterly loss of $0.14 per share, missing the $0.11-per-share consensus estimate; revenue of $14.29 million also came in slightly below expectations.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) has been given an average recommendation of "Hold" by the six brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $10.00.

A number of equities analysts have issued reports on IVVD shares. Weiss Ratings upgraded Invivyd from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, September 8th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Invivyd in a research note on Thursday, August 27th. BTIG Research reaffirmed a "buy" rating on shares of Invivyd in a research report on Monday, September 14th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Invivyd in a report on Tuesday, September 29th.

Invivyd Stock Down 3.7%

Shares of NASDAQ IVVD opened at $0.57 on Wednesday. The company has a market cap of $169.31 million, a price-to-earnings ratio of -1.74 and a beta of 1.20. Invivyd has a 52 week low of $0.53 and a 52 week high of $3.07. The firm's fifty day moving average is $0.74 and its 200 day moving average is $1.11.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The business had revenue of $14.29 million for the quarter, compared to the consensus estimate of $14.40 million. Equities research analysts anticipate that Invivyd will post -0.51 earnings per share for the current year.

Insider Transactions at Invivyd

In other Invivyd news, insider Jill Andersen sold 30,706 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total transaction of $25,793.04. Following the completion of the transaction, the insider owned 283,774 shares of the company's stock, valued at $238,370.16. This represents a 9.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 228,024 shares of company stock worth $176,540. 12.25% of the stock is currently owned by company insiders.

Institutional Trading of Invivyd

A number of institutional investors have recently bought and sold shares of the stock. United Capital Financial Advisors LLC bought a new position in Invivyd in the 2nd quarter valued at $84,000. Bank of America Corp DE purchased a new stake in shares of Invivyd during the 2nd quarter worth $311,000. Jupiter Topco LLC purchased a new position in Invivyd in the second quarter valued at about $30,048,000. ADAR1 Capital Management LLC bought a new position in shares of Invivyd during the 2nd quarter worth approximately $3,322,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Invivyd during the 2nd quarter valued at $52,000. 70.36% of the stock is currently owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc. is a biotechnology company focused on developing antibody-based medicines designed to prevent and treat infectious diseases. The company uses its antibody discovery and engineering technologies to create broadly neutralizing antibodies intended to remain effective as viruses evolve. Invivyd's lead product is pemivibart, marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration granted pemivibart an Emergency Use Authorization in 2024 for pre-exposure prophylaxis against COVID-19 in certain individuals who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to vaccination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.